-
Je něco špatně v tomto záznamu ?
Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis
E. Laukhtina, K. Mori, H. Mostafaei, AS. Merseburger, P. Nyirady, M. Moschini, F. Quhal, VM. Schuettfort, B. Pradere, RS. Motlagh, D. Enikeev, SF. Shariat, EA. Of Urology-Young Academic Urologists Eau-Yau Urothelial Carcinoma Working Group
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, metaanalýza, práce podpořená grantem, systematický přehled
NLK
PubMed Central
od 2015 do Před 1 rokem
ProQuest Central
od 2009-01-01 do 2021-04-30
Health & Medicine (ProQuest)
od 2009-01-01 do 2021-04-30
Public Health Database (ProQuest)
od 2009-01-01 do 2021-04-30
PubMed
34078134
DOI
10.2217/imt-2020-0305
Knihovny.cz E-zdroje
- MeSH
- imunoterapie škodlivé účinky metody MeSH
- karcinom z přechodných buněk farmakoterapie MeSH
- lidé MeSH
- nádory močového měchýře farmakoterapie MeSH
- protinádorové látky imunologicky aktivní terapeutické užití MeSH
- síťová metaanalýza MeSH
- záchranná terapie metody MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
- práce podpořená grantem MeSH
- systematický přehled MeSH
Aim: We aimed to compare the mortality rates related to adverse events (AEs) and discontinuation of treatment due to toxicity as well as all AEs of currently used regimens of second-line treatment strategies for advanced or metastatic urothelial carcinoma of the bladder. Methods: The MEDLINE and EMBASE databases were searched for articles according to the PRISMA extension statement for network meta-analysis. Results: Five trials comprising 2205 patients met our eligibility criteria. It is highly likely that immunotherapy, as single regimen, has the lowest rates of motor and sensory neuropathies, constipation, abdominal pain, alopecia, decreased appetite, vomiting and febrile neutropenia. Immunotherapy, in combination regimen, has the lowest rates of anemia and fatigue. Conclusion: Immunotherapy, especially as single regimen, demonstrated the highest favorable tolerability to most AEs.
Department of Urology 2nd Faculty of Medicine Charles University Prague 15006 Czech Republic
Department of Urology Campus Lübeck University Hospital Schleswig Holstein Lübeck 23562 Germany
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna 1090 Austria
Department of Urology King Fahad Specialist Hospital Dammam 32253 Saudi Arabia
Department of Urology Luzerner Kantonsspital Lucerne 6000 Switzerland
Department of Urology Semmelweis University Budapest 1082 Hungary
Department of Urology The Jikei University School of Medicine Tokyo Japan
Department of Urology University Medical Center Hamburg Eppendorf Hamburg 20251 Germany
Department of Urology University of Texas Southwestern Dallas TX 75390 USA
Department of Urology Weill Cornell Medical College New York NY 14853 USA
Institute for Urology and Reproductive Health Sechenov University Moscow 119991 Russia
Karl Landsteiner Institute of Urology and Andrology Vienna 1010 Austria
Research Center for Evidence Based Medicine Tabriz University of Medical Sciences Tabriz 5166 Iran
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012316
- 003
- CZ-PrNML
- 005
- 20220506130845.0
- 007
- ta
- 008
- 220425s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2217/imt-2020-0305 $2 doi
- 035 __
- $a (PubMed)34078134
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Institute for Urology & Reproductive Health, Sechenov University, Moscow, 119991, Russia $1 https://orcid.org/0000000289530272
- 245 10
- $a Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis / $c E. Laukhtina, K. Mori, H. Mostafaei, AS. Merseburger, P. Nyirady, M. Moschini, F. Quhal, VM. Schuettfort, B. Pradere, RS. Motlagh, D. Enikeev, SF. Shariat, EA. Of Urology-Young Academic Urologists Eau-Yau Urothelial Carcinoma Working Group
- 520 9_
- $a Aim: We aimed to compare the mortality rates related to adverse events (AEs) and discontinuation of treatment due to toxicity as well as all AEs of currently used regimens of second-line treatment strategies for advanced or metastatic urothelial carcinoma of the bladder. Methods: The MEDLINE and EMBASE databases were searched for articles according to the PRISMA extension statement for network meta-analysis. Results: Five trials comprising 2205 patients met our eligibility criteria. It is highly likely that immunotherapy, as single regimen, has the lowest rates of motor and sensory neuropathies, constipation, abdominal pain, alopecia, decreased appetite, vomiting and febrile neutropenia. Immunotherapy, in combination regimen, has the lowest rates of anemia and fatigue. Conclusion: Immunotherapy, especially as single regimen, demonstrated the highest favorable tolerability to most AEs.
- 650 _2
- $a protinádorové látky imunologicky aktivní $x terapeutické užití $7 D000074322
- 650 _2
- $a karcinom z přechodných buněk $x farmakoterapie $7 D002295
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoterapie $x škodlivé účinky $x metody $7 D007167
- 650 _2
- $a síťová metaanalýza $7 D000071076
- 650 _2
- $a záchranná terapie $x metody $7 D016879
- 650 _2
- $a nádory močového měchýře $x farmakoterapie $7 D001749
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a metaanalýza $7 D017418
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a systematický přehled $7 D000078182
- 700 1_
- $a Mori, Keiichiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/0000000261476569
- 700 1_
- $a Mostafaei, Hadi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz , 5166, Iran $1 https://orcid.org/0000000155961771
- 700 1_
- $a Merseburger, Axel S $u Department of Urology, Campus Lübeck, University Hospital Schleswig-Holstein, Lübeck , 23562, Germany $1 https://orcid.org/0000000164673931
- 700 1_
- $a Nyirady, Peter $u Department of Urology, Semmelweis University, Budapest, 1082, Hungary $1 https://orcid.org/0000000270374919
- 700 1_
- $a Moschini, Marco $u Department of Urology, Luzerner Kantonsspital, Lucerne , 6000, Switzerland $u Department of Urology & Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele, Milan , 20132, Italy $1 https://orcid.org/0000000230842458
- 700 1_
- $a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, King Fahad Specialist Hospital, Dammam , 32253, Saudi Arabia $1 https://orcid.org/0000000281636953
- 700 1_
- $a Schuettfort, Victor M $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, 20251, Germany $1 https://orcid.org/0000000271140508
- 700 1_
- $a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $1 https://orcid.org/0000000277688558
- 700 1_
- $a Motlagh, Reza Sari $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $1 https://orcid.org/0000000238199911
- 700 1_
- $a Enikeev, Dmitry $u Institute for Urology & Reproductive Health, Sechenov University, Moscow, 119991, Russia $1 https://orcid.org/0000000171692209
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Institute for Urology & Reproductive Health, Sechenov University, Moscow, 119991, Russia $u Department of Urology, Weill Cornell Medical College, New York, NY 14853, USA $u Department of Urology, University of Texas Southwestern, Dallas, TX 75390, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague , 15006, Czech Republic $u Karl Landsteiner Institute of Urology & Andrology, Vienna , 1010, Austria $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman , 11942, Jordan $1 https://orcid.org/0000000266276179
- 700 1_
- $a Of Urology-Young Academic Urologists Eau-Yau Urothelial Carcinoma Working Group, European Association
- 773 0_
- $w MED00175821 $t Immunotherapy $x 1750-7448 $g Roč. 13, č. 11 (2021), s. 917-929
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34078134 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130838 $b ABA008
- 999 __
- $a ok $b bmc $g 1789764 $s 1163517
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 13 $c 11 $d 917-929 $e 20210603 $i 1750-7448 $m Immunotherapy $n Immunotherapy $x MED00175821
- LZP __
- $a Pubmed-20220425